Amylin Analogs for Weight Loss: The Class, Explained

A plain-language guide to the amylin drug class: what the hormone does, where each investigational agent stands, and why amycretin does not belong on the list.

You have probably noticed the same thing a lot of patients have. The list of new weight-loss drug names keeps getting longer, and one word keeps showing up underneath them: amylin. Cagrilintide, petrelintide, eloralintide, CagriSema, amycretin. On their own they sound like a jumble of syllables, but most of them pull on the same biological thread, and once you can see the thread the whole confusing pipeline gets easier to follow. This is a plain-language tour of the amylin class. What amylin is, why researchers keep pairing it with GLP-1, and where each of these agents actually stands. One thing to say up front, and we will say it more than once: with a single exception, everything named here is investigational and not FDA-approved for weight loss.

What amylin actually is

Amylin is a hormone your own body already makes. Its formal name is islet amyloid polypeptide, or IAPP, and it is a small peptide, 37 amino acids long. Your pancreatic beta cells release it right alongside insulin every time you eat. So insulin and amylin are partners. Insulin manages the sugar in a meal; amylin helps manage the meal itself.

It does that in a few ways at once. Amylin slows how fast your stomach empties, so food stays with you longer and fullness arrives sooner. It signals the pancreas to ease off glucagon, a hormone that pushes blood sugar up. And it acts on satiety centers in the hindbrain, in a region called the area postrema, which is part of how your brain decides you have had enough. Put simply, amylin is one of the signals that says stop eating. Researchers have wanted to bottle that signal for a long time.

Why researchers keep pairing amylin with GLP-1

GLP-1 is the hormone behind the medicines most people have already heard of, and it works through its own set of pathways to blunt appetite and slow digestion. If you want the full picture of that mechanism, we walk through it in how GLP-1 works in the body. The short version is that GLP-1 and amylin are not the same signal. They quiet appetite by different routes.

That difference is the whole reason the two keep getting combined. The idea is that amylin adds a layer of fullness on top of what GLP-1 already does, rather than just pushing harder on the same lever. In studies so far, adding an amylin agent to a GLP-1 agent has tended to produce more weight loss than either one alone. It is a promising line of thinking. It is also still being tested, which is the honest frame for nearly everything in this class.

Pramlintide: the one that is already approved

There is exactly one amylin analog you can get a prescription for today, and it is not a weight-loss drug. Pramlintide, sold as Symlin, was the first synthetic amylin analog, and the FDA approved it back in 2005. Its approved job is narrow. It is an add-on to mealtime insulin for some people with type 1 or type 2 diabetes, to help steady blood sugar around meals.

People noticed years ago that pramlintide also tended to nudge weight down, which is part of what pointed researchers toward amylin as a weight target in the first place. But approved is a specific word. Pramlintide is approved as a diabetes medicine, not as an obesity treatment, and it is not something anyone should repurpose on their own. Think of it as the early proof of concept, not the finished product.

The investigational amylin analogs

The newer molecules are where the excitement lives, and they are all still in development. These are the pure amylin analogs, meaning each molecule is built to act like amylin, and each is designed to be given once weekly.

• Cagrilintide (Novo Nordisk) is a long-acting amylin analog. In a large phase 3 trial called REDEFINE 1, cagrilintide on its own produced about 11.8% mean weight loss at 68 weeks. It is not FDA-approved as a standalone drug.
• Petrelintide (Zealand Pharma, partnered with Roche) is another once-weekly amylin analog. In its phase 2 trial, ZUPREME-1, it produced up to roughly 10.7% mean weight loss at 42 weeks, compared with 1.7% for placebo, and researchers reported stomach-related side effects that looked close to placebo. It is heading into phase 3 and is not approved.
• Eloralintide (Eli Lilly, the company behind tirzepatide, sold as Mounjaro and Zepbound; this clinic is not affiliated with those brands) is a selective amylin receptor agonist. A 48-week phase 2 trial reported mean weight loss up to about 20.1%, versus 0.4% for placebo. It too is moving toward phase 3 and is not approved.

Resist the urge to line those percentages up like a leaderboard. They come from different trials with different designs, different lengths, and different groups of people, so a bigger number in one study does not mean one drug beats another. Each figure only means something inside its own trial. We keep a wider view of this crowded field in the 2026 weight-loss drug pipeline.

Where CagriSema fits

CagriSema is the combination that put this class on the map for a lot of people. It pairs cagrilintide, the amylin analog above, with semaglutide, a GLP-1 medicine. Semaglutide is the active ingredient in Ozempic and Wegovy, which are Novo Nordisk products, and this clinic is not affiliated with those brands. So CagriSema is, quite literally, the amylin-plus-GLP-1 idea packed into one weekly shot.

In that same REDEFINE 1 trial, CagriSema reached about 22.7% mean weight loss at 68 weeks, with the semaglutide arm around 16.1% and the cagrilintide arm around 11.8%, against 2.3% for placebo. Those are the efficacy figures, roughly the results among people who stayed on the full treatment, which is one legitimate way to read a trial but not the only one. Novo Nordisk filed for FDA approval of CagriSema in weight management in December 2025. As of the middle of 2026 it is under review and not approved, with a decision expected sometime during the year. We go deeper on all of this in our CagriSema explainer.

Why amycretin belongs in a different box

Here is the distinction that trips up almost everyone. Amycretin gets mentioned in the same breath as the drugs above, but it is not a pure amylin analog. It is a single molecule engineered to activate both the GLP-1 receptor and the amylin receptor at once, what researchers call a unimolecular co-agonist. CagriSema reaches both targets by combining two separate peptides. Amycretin reaches both with one. That is a real design difference, not a technicality.

Amycretin, also from Novo Nordisk, is being studied as both an injection and a pill, and the early data has been striking, with one subcutaneous dose reaching around 22% weight loss at 36 weeks in an early trial. It moved into phase 3 in early 2026 and is not approved. Because it is its own kind of thing, we gave it a separate write-up in amycretin explained. If you take one fact from this section, make it this: amylin analog and amylin co-agonist are not interchangeable terms.

What this means for you right now

Read the trial numbers the way a careful clinician does. They are averages, pulled from studies of different sizes and lengths, run on people who are not you. An average is not a promise, and no percentage here is a starting dose or a guarantee. Individual results vary, sometimes quite a bit. And none of these novel agents, from cagrilintide to CagriSema to petrelintide to eloralintide to amycretin, is something you can be prescribed today. Pramlintide exists, but only as a diabetes medicine.

So what is the point of learning all this now? Mostly so the headlines stop pushing you around. When the next amylin drug lands in the news over the coming year or two, you will already know what it is, what class it belongs to, and what questions to ask. The tools that are actually available today, including GLP-1 based care, are still the ones worth talking through with a licensed clinician who knows your history. That conversation, not a press release, is where any real decision should happen. If you want to think it through with someone, that is exactly what we are here for.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.